(Alliance News) - PureTech Health PLC on Wednesday said its subsidiary Vedanta Biosciences has received fast-track designation for its VE202 treatment. Read More
(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arix Bioscience PLC on Wednesday said net asset value increased in its latest half year, but has since launched a strategic review due to "unfavourable" conditions while Chief Executive Officer Robert Lyne prepares to step down. Read More
(Alliance News) - Stock prices in London opened higher on Tuesday, as UK markets return from a long bank holiday weekend and news that UK shop price inflation decelerated in August. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - PureTech Health PLC on Wednesday said that it has started the next stage of trials for LYT-300, in order to test whether the therapy could be used to treat anxiety disorders. Read More
(Alliance News) - PureTech Health PLC on Wednesday said its founded entity, Akili Inc, released an attention deficit hyperactivity disorder treatment for adult patients. Read More
(Alliance News) - PureTech Health PLC on Tuesday said its founded entity, Vedanta Biosciences, has been granted fast track designation from the US Food & Drug Administration for its bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection. Read More
PureTech Health PLC - Boston-based biotechnology company - Says its founded entity, Akili, announced clinical trial for video game-based therapy, EndeavorRx, showed improvement in attention and quality of life for people with attention deficit hyperactivity disorder. Notes attention improved in more than 80% of adults with ADHD, while over a third of participants "no longer exhibited an attention deficit following treatment." Read More
(Alliance News) - PureTech Health PLC on Friday said its loss widened in 2022 and revenue declined, though it hailed an "exceptional" year and expects further success in 2023. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on xxxday and not separately reported by Alliance News: Read More
(Alliance News) - PureTech Health PLC on Monday said that its founded entity, Vedanta Biosciences, has seen positive results for its lead programme, VE303. Read More
(Alliance News) - Stock prices in London were largely lower at midday on Thursday, raised UK interest rates by 25 basis points on Thursday, as widely expected, and indicated that further tightening in monetary policy may be required. Read More
(Alliance News) - PureTech Health PLC on Thursday said Royalty Pharma PLC has acquired an interest in PureTech's royalty in Karuna Therapeutics Inc's KarXT schizophrenia treatment. Read More
(Alliance News) - PureTech Health PLC on Monday said its founded entity, Karuna Therapeutics Inc announced its phase 3 EMERGENT-3 trial of KarXT in Schizophrenia has met its primary endpoint. Read More
